Expanded Access for Pembrolizumab (MK-3475)
Expanded Access for Pembrolizumab (MK-3475) to Patients With Melanoma or Glioblastoma / Glioma After Failed Standart Therapy, at High Mutational Load Which is Confirmed by the Results of Molecular-genetic Analysis of Tumor Tissue.
Sponsor: Center Trials & Treatment
A observational or N/A phase clinical study on Glioblastoma Multiforme and Glioblastoma by Gene Expression Profile, this trial is ongoing. The trial is conducted by Center Trials & Treatment and has accumulated 8 data snapshots since 2026. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
No Longer Available
-
Jul 2024 — Sep 2024 [monthly]
No Longer Available
-
Jan 2021 — Jul 2024 [monthly]
No Longer Available
-
Jun 2018 — Jan 2021 [monthly]
No Longer Available
-
Apr 2018 — Jun 2018 [monthly]
No Longer Available
Phase: NA → None
▶ Show 3 earlier versions
-
Jan 2018 — Apr 2018 [monthly]
No Longer Available NA
Status: Temporarily Not Available → No Longer Available
-
Dec 2017 — Jan 2018 [monthly]
Temporarily Not Available NA
Status: Available → Temporarily Not Available
-
Nov 2017 — Dec 2017 [monthly]
Available NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Center Trials & Treatment
For direct contact, visit the study record on ClinicalTrials.gov .